<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-1-038.anc" start="21081" end="21087" sStart="20897" offset="0" sid="null" wn="5" wnkey="window%1:28:00::" text="Key design issues with regard to the use of diffusion and perfusion MRI in stroke trials are proposed in Table 7. MRI-based recruitment into trials with a time &lt;b&gt;window&lt;/b&gt; of 6 h has proven feasible, as has specific selection based on lesion size, location, and the diffusion-perfusion mismatch." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-1-038.anc" start="4162" end="4169" sStart="null" offset="0" sid="null" wn="2" wnkey="success%1:04:00::" text="The results of that trial suggested that a more prolonged study duration, increased expense and potential delay in treatment to complete a screening test may be justified by the greater chance of demonstrating therapeutic &lt;b&gt;success&lt;/b&gt; using a more homogeneous and rational selection of patients." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-1-038.anc" start="4162" end="4169" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" text="The results of that trial suggested that a more prolonged study duration, increased expense and potential delay in treatment to complete a screening test may be justified by the greater chance of demonstrating therapeutic &lt;b&gt;success&lt;/b&gt; using a more homogeneous and rational selection of patients." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/cvm-2-1-038.anc" start="16350" end="16356" sStart="null" offset="0" sid="null" wn="4" wnkey="show%2:39:00::" text="The latter has been found for the Glycine Antagonist in Neuroprotection (GAIN) trials, which &lt;b&gt;showed&lt;/b&gt; no effect on clinical or MRI surrogate outcomes [ 33, 34]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="6309" end="6314" sStart="null" offset="115" sid="r7.serve.v.0576" wn="1" wnkey="serve%2:42:03::" text="The target pathology revealed by MRI also represents the biological marker of the disease that can serve as a surrogate measure for assessing the effects of a therapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-1-038.anc" start="7331" end="7336" sStart="null" offset="0" sid="null" wn="6" wnkey="power%1:10:00::" text="The goal of image-based patient selection is to narrow the range of patient characteristics, leading to a more homogeneous sample, reducing within-group variance, and increasing the statistical &lt;b&gt;power&lt;/b&gt; of the experimental design to demonstrate efficacy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-1-038.anc" start="7331" end="7336" sStart="null" offset="0" sid="null" wn="3" wnkey="power%1:09:01::" text="The goal of image-based patient selection is to narrow the range of patient characteristics, leading to a more homogeneous sample, reducing within-group variance, and increasing the statistical &lt;b&gt;power&lt;/b&gt; of the experimental design to demonstrate efficacy." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="4381" end="4387" sStart="null" offset="134" sid="r9.normal.j.0563" wn="3" wnkey="normal%3:00:03::" text="The appeal of MRI methods is that, whereas the standard CT examination of acute ischemic stroke will typically appear normal in the first hours after stroke onset, the methods of magnetic resonance angiography, perfusion weighted imaging (PWI), and diffusion weighted imaging (DWI) provide information on arterial patency, tissue blood flow, and parenchymal injury from the earliest times after onset of ischemic symptoms in a brief, non-invasive examination." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-1-038.anc" start="13184" end="13189" sStart="null" offset="0" sid="null" wn="3" wnkey="image%1:06:00::" text="&lt;b&gt;Image&lt;/b&gt; data processing and volumetric analysis were performed at a single central laboratory using a single expert reader blinded to patient clinical severity and treatment assignment." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="4846" end="4850" sStart="null" offset="65" sid="r10.high.j.0638" wn="1" wnkey="high%3:00:02::" text="1) detects tissue injury within minutes of ischemia, has high sensitivity and specificity for the diagnosis of ischemic stroke, and permits measurement of lesion volumes that correlate with clinical severity and prognosis [ 6, 7, 8, 9, 10, 11, 12]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="1828" end="1833" sStart="null" offset="271" sid="r8.1.great.j.0264" wn="1" wnkey="great%5:00:01:large:00" text="Except for the trials of intravenous recombinant tissue-plasminogen activator (rt-PA) in the treatment of ischemic stroke within the first 3 h [ 1], this traditional approach has lead to no approved therapies for stroke, and has lead to a great degree of pessimism with regard to thrombolysis beyond 3 h and with regard to the concept of neuroprotection in stroke." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="12093" end="12100" sStart="null" offset="13" sid="r11.benefit.n.0826" wn="2" wnkey="benefit%1:07:00::" text="The clinical benefit for neuroprotective drugs is mediated through a reduction in cell death and brain tissue loss." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="9649" end="9656" sStart="null" offset="98" sid="r11.benefit.n.0721" wn="2" wnkey="benefit%1:07:00::" text="In clinical trial programs that depend solely on clinical endpoints as indices of benefit, drugs may be brought to phase III testing - costing several years and tens of millions of dollars - without the slightest evidence that the drug will have the therapeutic effect observed in the experimental model." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="9542" end="9549" sStart="null" offset="183" sid="r11.benefit.n.0517" wn="2" wnkey="benefit%1:07:00::" text="The fundamental premise of drug discovery and development in acute stroke is that treatments that reduce lesion size are those most likely to lead to clinical benefit." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="3110" end="3117" sStart="null" offset="227" sid="r11.benefit.n.0163" wn="2" wnkey="benefit%1:07:00::" text="Patients in PROACT II [ 2], however, were selected based on evidence of arterial occlusions at the M1 or M2 levels of the middle cerebral artery by conventional arteriography, and a significant clinical benefit was observed when thromboly-sis was initiated up to 6 h from symptom onset (median time to treat, 5.3 h)." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="18599" end="18606" sStart="null" offset="133" sid="r11.benefit.n.0533" wn="2" wnkey="benefit%1:07:00::" text="The issue with regard to MRI as a surrogate in stroke trials is whether it is 'reasonably likely to predict clinical benefit'." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="18328" end="18335" sStart="null" offset="115" sid="r11.benefit.n.0377" wn="2" wnkey="benefit%1:07:00::" text="Such surrogate endpoints are considered not to be validated because, while suggestive of clinical benefit, their relationship to clinical outcomes, such as morbidity and mortality, is not proven&quot; [ 35] (emphasis added)." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-1-038.anc" start="19320" end="19327" sStart="null" offset="132" sid="r11.benefit.n.0654" wn="2" wnkey="benefit%1:07:00::" text="A benefit on the surrogate may be acceptable as an independent source of confirmatory data in support of a clinical benefit seen in a single trial." />
  </sentences>
</list>